Nabahat Shafi

Nabahat Shafi

Auto-generated profile, based on publicly available information

Nabahat Shafi

Department of Medicine Dow University of Health Sciences Karachi Pakistan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2026 in Clinical Case Reports
Verified
Journal Article
Open access
MMMaliha Malik
Maliha Malik
HAHammad Amjad
Hammad Amjad
KMKhadija Malik
Khadija Malik
MSMuddassir Syed Saleem
Muddassir Syed Saleem
SAShanzay Akhtar
Shanzay Akhtar
SJSamar Abbas Jaffri
Samar Abbas Jaffri
Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide for weight loss while on empagliflozin and basal–bolus insulin therapy. She presented with severe vomiting and profound metabolic acidosis (pH 6.96, bicarbonate 1.5 mmol/L) despite only modest hyperglycemia (glucose 190–200 mg/dL). The severity of acidosis necessitated intubation and intravenous bicarbonate therapy. Laboratory findings revealed elevated amylase (688 U/L), suggesting possible tirzepatide‐associated pancreatic stress. No infection or other precipitating factor was identified. The patient recovered after intensive insulin and fluid replacement. This case highlights the risk of severe euDKA with the administration of tirzepatide in T1DM, particularly in combination with an SGLT2 inhibitor. Clinicians should keep a high index of suspicion for ketoacidosis in such patients despite normal or mildly elevated glucose levels and inform them of early detection of symptoms and sick day management.

9 May 2024 in Hygiene and Environmental Health Advances
Verified
Journal Article
Open access
JYJuvairia Yousuf
Juvairia Yousuf
LALaiba Afaq
Laiba Afaq
UAUzma Aslam
Uzma Aslam
NSNabahat Shafi
Nabahat Shafi
ZRZainab Syyeda Rahmat
Zainab Syyeda Rahmat

2 July 2026 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
ANAbdullah Nadeem
Abdullah Nadeem
MSMuddassir Syed Saleem
Muddassir Syed Saleem
ARAmara Ahmad Rai
Amara Ahmad Rai
BKBarina Khan
Barina Khan
ASAreeba Shafqat
Areeba Shafqat
URUbaid Ur Rehman
Ubaid Ur Rehman

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
SKSaifullah Khan
Saifullah Khan
AAAlisha Ahmad
Alisha Ahmad
AAAiza Ahsan
Aiza Ahsan
EJEvardo Barros de Deus Nunes Junior
Evardo Barros de Deus Nunes Junior
Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.

26 May 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
Sadia QaziSadia Qazi
Sadia Qazi
AAArsalan Ahmed
Arsalan Ahmed
MAMazhar Ali
Mazhar Ali
MIMuhammad Usman Iqbal
Muhammad Usman Iqbal
EAEshal Atif
Eshal Atif
MMMuhammad Atif Mazhar
Muhammad Atif Mazhar
Background: The efficacy of tenecteplase for acute ischemic stroke (AIS) beyond 4.5 h remains uncertain, particularly across care pathways with and without endovascular thrombectomy (EVT). We performed an updated systematic review and meta-analysis using an EVT-stratified framework. Methods: PubMed, Embase, Scopus, and the Cochrane Library were searched through February 2026 for randomized controlled trials comparing tenecteplase with control in imaging-selected patients with AIS presenting 4.5–24 h from last known well. The primary outcome was excellent functional outcome (mRS 0–1) at 90 days. Secondary outcomes were good functional outcome (mRS 0–2), recanalization, early neurological improvement, symptomatic intracranial hemorrhage, and 90-day mortality. Random-effects models with Hartung–Knapp adjustment were used. Subgroup analyses by EVT availability were interpreted as exploratory because of the limited number of trials. Results: Five trials including 1844 patients were analyzed. Tenecteplase improved excellent functional outcome (RR 1.25, 95% CI 1.10–1.42; p = 0.0005) with no heterogeneity (I2 = 0%) and no interaction by EVT status (p-interaction = 0.961). Good functional outcome was not significantly different overall (RR 1.10, 95% CI 0.97–1.24; p = 0.135). Significant subgroup interactions were observed for recanalization (p-interaction = 0.004) and early neurological improvement (p-interaction = 0.002), with benefits concentrated in non-EVT settings. However, the larger effect on recanalization did not translate proportionally into functional recovery, supporting separation of vessel-opening outcomes from patient-centered outcomes. Symptomatic intracranial hemorrhage showed a nonsignificant increase in four estimable studies (RR 1.88, 95% CI 0.94–3.78; p = 0.074), whereas 90-day mortality did not differ significantly (RR 1.11, 95% CI 0.85–1.43; p = 0.43). Conclusions: In imaging-selected AIS presenting 4.5–24 h after onset, tenecteplase improved excellent functional outcome irrespective of EVT availability, while benefits for recanalization and early neurological improvement were largely confined to non-EVT settings. Because recanalization is an intermediate endpoint, these findings should not be interpreted as proof of a proportional clinical benefit. Future extended-window trials should specify EVT status.